GT Biopharma, Inc.GTBPNASDAQ
Loading
Year-over-year earnings per share growth rate
| Period | Value |
|---|---|
| Q4 2025 | -498.80% |
| Q3 2025 | -50.91% |
| Q2 2025 | -66.67% |
| Q1 2025 | 83.42% |
| Q4 2024 | -30.07% |
| Q3 2024 | 29.49% |
| Q2 2024 | -32.32% |
| Q1 2024 | 23.72% |
| Q4 2023 | -21.47% |
| Q3 2023 | -18.79% |
| Q2 2023 | -609.52% |
| Q1 2023 | 95.55% |
| Q4 2022 | -512.99% |
| Q3 2022 | 73.08% |
| Q2 2022 | 43.03% |
| Q1 2022 | -141.35% |
| Q4 2021 | 60.08% |
| Q3 2021 | -19.77% |
| Q2 2021 | 92.08% |
| Q1 2021 | -1553.61% |
| Q4 2020 | -418.75% |
| Q3 2020 | 69.23% |
| Q2 2020 | -407.32% |
| Q1 2020 | -10.81% |
| Q4 2019 | 99.86% |
| Q3 2019 | -28482.42% |
| Q2 2019 | 97.98% |
| Q1 2019 | -3070.42% |
| Q4 2018 | 99.94% |
| Q3 2018 | -2511.09% |
| Q2 2018 | 10.00% |
| Q1 2018 | -4900.00% |
| Q4 2017 | 99.95% |
| Q3 2017 | -64.20% |
| Q2 2017 | 59.81% |
| Q1 2017 | -2412.42% |
| Q4 2016 | 98.73% |
| Q3 2016 | -316.08% |
| Q2 2016 | -91.23% |
| Q1 2016 | 1051.19% |